Matt Gline, Roivant CEO (John Sciulli/Getty Images for GLG)
February 14, 2022 10:25 AM EST
Startups
Pharma

Roivant re­veals its newest 'vant,' try­ing to re­boot an Ei­sai blood can­cer pro­gram and out­flank Mer­ck, Bris­tol My­ers

Max Gelman

Senior Editor

Roivant Sci­ences wel­comed the newest ad­di­tion to its fam­i­ly of “vants” on Mon­day dur­ing its fourth quar­ter and full-year 2021 up­date.

The bio­phar­ma un­veiled Hema­vant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times